Mediwhale, a Korean medical artificial intelligence company specializing in retinal-based cardiovascular disease prediction, has closed a KRW 20 billion ($14.5 million USD) SeriesC funding round. The latest raise brings Medweil’s total cumulative funding to KRW 51.2 billion.
Premier Partners led the round as the primary investor, citing the company’s proprietary retinal AI technology and strong commercial traction as key drivers of the investment decision. KB Investment, Quad Asset Management, IMM Investment, Hana Ventures, AON Investment, and Startup Partners participated as co-investors.
Mediwhale’s flagship product, Doctor Nun CVD, uses AI to analyze retinal images and predict cardiovascular disease risk — a non-invasive diagnostic approach that has gained traction among primary care providers. The company is currently pursuing U.S. FDA De Novo authorization to gain entry into the American market.
The newly secured capital will be deployed across several strategic priorities. Medweil plans to expand the domestic and international market presence of its flagship product, Doctor Nun CVD, while simultaneously advancing U.S. FDA De Novo authorization and conducting global clinical trials.
Mediwhale is also actively preparing for a Kosdaq listing through the technology special listing pathway, targeting the first half of 2027.
